Interpreting the EHR-derived Glucosamine Signal in Alzheimer's disease: A Comment on Hawkinson et al. (2026)
In "Hyperglycosylation is a metabolic driver of Alzheimer’s disease" (DOI: 10.1038/s42255-026-01538-4, PMID: 42265388), Hawkinson et al. provide experimental evidence that D-glucosamine (GlcN)-mediated hyperglycosylation may contribute to Alzheimer’s disease (AD) pathology in 5xFAD mice. They further report that GlcN use documented in electronic health records is associated with higher mortality among people with AD and related dementias and faster progression from mild cognitive impairment to dementia. These findings raise an important clinical safety question, but the reported associations are insufficient to support a causal interpretation. Limited confounder adjustment and reliance on clinical documentation leave the estimates vulnerable to confounding by indication and measurement error. A subsequent analysis of data from the National Alzheimer’s Coordinating Center observed similar patterns for other supplements. The available human evidence therefore does not establish GlcN as a driver of AD progression.
Authors
- Elisa Araldi (ORCID: https://orcid.org/0000-0002-6596-6784)
- Riccardo Perrone (ORCID: https://orcid.org/0009-0000-9456-8569)
- P. Borchert (ORCID: https://orcid.org/0009-0009-8156-3131)
- Michael Ristow (ORCID: https://orcid.org/0000-0003-2109-2453)
- Roberto Pili (ORCID: https://orcid.org/0009-0009-7656-8886)
Institutions
- University of Parma (IT)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ETH Zurich (CH)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24352071
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- preprint